Drug · DIN 02253283
GLEEVEC
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since October 25, 2004; first marketed October 25, 2004.
- Drug Identification Number (DIN)
- 02253283
- Company (DIN owner)
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Imatinib L01EA01
- Class
- Human
- Record last updated
- June 17, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| IMATINIB (IMATINIB MESYLATE) | 400 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- April 6, 2022: NOC 27926Supplement to a New Drug Submission (SNDS) · To update the Product Monograph
- June 2, 2004: NOC 4271Supplement to a New Drug Submission (SNDS) · New dosage form: tablets
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “gleevec”. A notice may cover another product or only some lots: read it to see what it covers.
- BCR-ABL Tyrosine Kinase Inhibitors [GLEEVEC (imatinib mesylate), TASIGNA (nilotinib), BOSULIF (bosutinib), SPRYCEL (dasatinib), ICLUSIG (ponatinib hydrochloride)] - Risk of Hepatitis B ReactivationMay 4, 2016 · Drugs · Product safety
- Gleevec (imatinib mesylate) - Advisories, Warnings and Recalls for Health ProfessionalsOctober 2, 2006 · Drugs
Other DINs named GLEEVEC
- DIN 02253275 · Marketed
- DIN 02244725 · Cancelled Post Market